HyperCVAD/MA方案治疗难治/复发成人急性淋巴细胞白血病疗效分析

摘要

Objective:To evaluate the efficacy and safety of HyperCVAD/MA regimen in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.Methods:The data of 21 cases of refractory/relapsed ALL patients treated with HyperCVAD/MA regimen from January 2010 to June 2016 were retrospectively analyzed.The efficacy and safety were evaluated.Results:The complete remission(CR) rate was 47.6％ in 21 cases,partial remission(PR) rate was 23.8％ and total effective rate was 71.4％.All patients suffered grade Ⅲ/Ⅳ bone marrow suppression,without the occurrence of life-threatening bleeding.Other adverse reactions included infection,liver and kidney toxicity,gastrointestinal reaction and skin rash.No treatment-related deaths occurred.Conclusion:HyperCVAD/MA regimen ould achieve a satisfactory result in treatment of refractory/relapsed adult ALL and adverse effects can be controlled.The long-term remission rate remains to be further observed.%目的:评估HyperCVAD/MA方案治疗难治/复发成人急性淋巴细胞白血病(ALL)的疗效和安全性.方法:回顾性分析21例2010年1月至2016年6月应用HyperCVAD/MA方案治疗的难治/复发成人ALL患者的有效性和安全性.结果:21例患者的完全缓解(CR)率为47.6％,部分缓解(PR)率为23.8％,总有效率为71.4％.所有患者均发生Ⅲ/Ⅳ度的骨髓抑制,未发生危及生命的出血现象,其他不良反应包括感染、肝肾毒性、胃肠道反应、皮疹等,无治疗相关死亡发生.结论:HyperCVAD/MA方案治疗难治/复发成人ALL的疗效满意,不良反应可控,但长期缓解率仍有待进一步观察.